Unser Qualitätsanspruch: Qualität Charge für Charge

Avextra steht für hochwertige Cannabis-Arzneimittel. Unser Schlüssel zum Erfolg: die eigene Kultivierung in Portugal sowie die Verknüpfung von Tradition und Hightech. Erfahren Sie mehr darüber im Video mit unserem CMO David Reckeweg-Lecompte.

Podcasts

Neil Smith zu Gast bei Planted mit Sara Payan.

Sara Payan diskutiert mit Neil Smith, dem COO von Avextra, über die europäische Cannabisbranche und die neuesten Entwicklungen in Forschung und Entwicklung. Hier finden Sie das Interview in englischer Sprache.

Pressemitteilungen

Aktuelle Pressemitteilungen von Avextra können Sie hier nachlesen.

Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.

Avextras stellt seine Allianz für evidenzbasierte Cannabis-Medizin vor und kündigt seine Unterstützung für BELCANTO an.

Bensheim, 18.10.2023 – Zum Deutschen Schmerzkongress in Mannheim kündigt Avextra seine Allianz für Evidenz mit dem Start von BELCANTO an: der ersten von Avextra unterstützten klinischen Studie für Onkologiepatient:innen. Zum…

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…

Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Avextra und die Deutsche Gesellschaft für Schmerzmedizin – mit der OCEAN Studie gemeinsam für mehr Evidenz in der Cannabis-Therapie

Auf dem virtuellen Deutschen Schmerz und Palliativtag im März haben Avextra und die Deutsche Gesellschaft für Schmerzmedizin (DGS) in einem Symposium ihre Pläne für eine gemeinsame prospektive, nicht-interventionelle, 12-wöchige Parallelgruppenstudie…

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…

Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.

Deutschland legt Plan zur begrenzten Legalisierung von Cannabis für den Freizeitgebrauch in abgestufter Form vor.

Heute ist ein historischer Tag in Deutschland, an dem große Fortschritte bei der Entstigmatisierung der Cannabispflanze gemacht wurden. Martha Lurther, CSO bei Avextra, teilt ihre Gedanken zu den deutschen Plänen.…

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…

Avextra erweitert Cannabis-Portfolio um neue Dronabinol-Lösung

Avextra erweitert Cannabis-Portfolio um neue Dronabinol-Lösung

Bensheim, 13. Februar 2023 – Apotheken können ab sofort Dronabinol – in Form einer öligen Zubereitung – über Avextra beziehen. Die Dronabinol-Lösung vereinfacht und beschleunigt die Herstellung der Rezepturherstellung. Das…

Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom

Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom

BENSHEIM, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading vertically-integrated manufacturer of Cannabis-based medicines located in Germany, is pleased to announce the successful…

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients

Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim…

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria

Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra Continues its European Expansion, Successfully Exporting Medical Cannabis Extracts to Italy

Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…

Germany unveils scaled-down recreational cannabis legalization plan

Germany unveils scaled-down recreational cannabis legalization plan

Today marked a historic day in Germany as major strides were made in removing the stigma surrounding this plant. Martha Lurther, CSO at Avextra shares her thoughts on Germany’s plans.…

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra AG Announces Closing of EU 17 Million Capital Raise

Avextra announces the closing of its EU 17 Million Convertible Loan Note (“CLN”) bridge capital raise. The CLN will automatically swap into equity at the next capital round currently in…

Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom

Avextra Successfully Exports Oil-Based Cannabis Medicines to the United Kingdom

BENSHEIM, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) — Avextra AG (“Avextra” or the “Company”), a leading vertically-integrated manufacturer of Cannabis-based medicines located in Germany, is pleased to announce the successful…

Medical Device Submission für ein Inhalationsdevice

Medical Device Submission für ein Inhalationsdevice

Avextra has commissioned the Leading Medical Device Specialists Activoris and Actarmo to prepare the EU Medical Device Submission for a Cannabis Extract Inhaler Together these three partners will develop a…

Eurox has rebranded as Avextra

Eurox has rebranded as Avextra

Bensheim, 14.9.2022 – Eurox has rebranded as Avextra. The leading manufacturer of cannabis-based medicines Made in Germany will premiere under its new name at the Expopharm Pharmacists’ Congress in Munich…

PRESSEKONTaKT

Lisa Schwede

Tel.: +49 30 408174037

E-Mail: press@avextra.com

DE